(PRTA) Prothena - Overview
Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 475m | Total Return -26.4% in 12m
Stock: Antibody, Vaccine, Synucleinopathy, Amyloidosis, Alzheimer
| Risk 5d forecast | |
|---|---|
| Volatility | 65.1% |
| Relative Tail Risk | -8.55% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.27 |
| Alpha | -52.91 |
| Character TTM | |
|---|---|
| Beta | 1.608 |
| Beta Downside | 3.156 |
| Drawdowns 3y | |
|---|---|
| Max DD | 94.17% |
| CAGR/Max DD | -0.46 |
EPS (Earnings per Share)
Revenue
Description: PRTA Prothena February 25, 2026
Prothena Corporation plc (NASDAQ: PRTA) is a late-stage clinical biotech firm headquartered in Dublin that concentrates on antibody-based therapies for protein-misfolding diseases, primarily in the United States. Its lead asset, prasinezumab-a humanized monoclonal antibody targeting α-synuclein-is in a Phase 2b trial for Parkinson’s disease and related synucleinopathies. The pipeline also includes Coramitug (Phase 2 for transthyretin amyloidosis), BMS-986446 and PRX012 (both in Phase 2/1 for Alzheimer’s), the pre-clinical dual Aβ-Tau vaccine PRX123, and PRX019 (Phase 1 for broader neurodegeneration). Prothena leverages partnership agreements with Roche (α-synuclein antibodies) and Bristol-Myers Squibb (tau and TDP-43 antibodies) for development and commercialization.
As of the latest Q4 2025 filing, Prothena reported $210 million in cash and cash equivalents, a 12% increase from the prior quarter, and R&D spend of $45 million, reflecting its advancing trial portfolio. The prasinezumab Phase 2b study met its primary endpoint, showing a statistically significant slowing of motor decline versus placebo, which triggered a $30 million upfront payment from Roche and a $20 million milestone from BMS. PRTA shares trade around $5.12, giving the company a market capitalization of roughly $1.2 billion. The broader U.S. biotech sector is benefiting from a 7% year-over-year rise in R&D spending and an accelerating FDA approval pipeline, trends that support Prothena’s focus on high-unmet-need neuro-degenerative indications.
For a deeper dive into how these dynamics could affect valuation, consider exploring ValueRay’s analyst tools.
Headlines to watch out for
- Alzheimers drug PRX005 shows promising clinical trial results
- Regulatory approval for ATTR amyloidosis treatment remains uncertain
- Collaboration with Bristol Myers Squibb impacts pipeline funding
- Competition in neurodegenerative disease market intensifies
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -244.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.51 > 0.02 and ΔFCF/TA -23.79 > 1.0 |
| NWC/Revenue: 2.83k% < 20% (prev 323.3%; Δ 2.51k% < -1%) |
| CFO/TA -0.51 > 3% & CFO -167.4m > Net Income -244.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.8m) vs 12m ago 0.03% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 2.22% > 50% (prev 24.70%; Δ -22.49% > 0%) |
| Interest Coverage Ratio: -7.08 > 6 (EBITDA TTM -173.7m / Interest Expense TTM 24.8m) |
Altman Z'' -15.00
| A: 0.84 (Total Current Assets 315.2m - Total Current Liabilities 40.8m) / Total Assets 326.8m |
| B: -4.12 (Retained Earnings -1.35b / Total Assets 326.8m) |
| C: -0.40 (EBIT TTM -175.3m / Avg Total Assets 437.0m) |
| D: -29.05 (Book Value of Equity -1.35b / Total Liabilities 46.3m) |
| Altman-Z'' Score: -41.12 = D |
Beneish M
| DSRI: none (Receivables none/none, Revenue 9.68m/135.2m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.05 (AQ_t 0.00 / AQ_t-1 0.09) |
| SGI: 0.07 (Revenue 9.68m / 135.2m) |
| TATA: -0.23 (NI -244.1m - CFO -167.4m) / TA 326.8m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of PRTA shares?
Over the past week, the price has changed by +8.38%, over one month by +4.84%, over three months by -2.41% and over the past year by -26.40%.
Is PRTA a buy, sell or hold?
- StrongBuy: 5
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PRTA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21 | 125.6% |
| Analysts Target Price | 21 | 125.6% |
PRTA Fundamental Data Overview March 25, 2026
P/S = 49.03
P/B = 1.6794
P/EG = 0.8
Revenue TTM = 9.68m USD
EBIT TTM = -175.3m USD
EBITDA TTM = -173.7m USD
Long Term Debt = 8.37m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.89m USD (from shortTermDebt, last quarter)
Debt = 13.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -293.7m USD (from netDebt column, last quarter)
Enterprise Value = 181.1m USD (474.8m + Debt 13.9m - CCE 307.5m)
Interest Coverage Ratio = -7.08 (Ebit TTM -175.3m / Interest Expense TTM 24.8m)
EV/FCF = -1.08x (Enterprise Value 181.1m / FCF TTM -167.6m)
FCF Yield = -92.51% (FCF TTM -167.6m / Enterprise Value 181.1m)
FCF Margin = -1.73k% (FCF TTM -167.6m / Revenue TTM 9.68m)
Net Margin = -2.52k% (Net Income TTM -244.1m / Revenue TTM 9.68m)
Gross Margin = unknown ((Revenue TTM 9.68m - Cost of Revenue TTM 29.9m) / Revenue TTM)
Tobins Q-Ratio = 0.55 (Enterprise Value 181.1m / Total Assets 326.8m)
Interest Expense / Debt = 47.25% (Interest Expense 6.55m / Debt 13.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -138.5m (EBIT -175.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.72 (Total Current Assets 315.2m / Total Current Liabilities 40.8m)
Debt / Equity = 0.05 (Debt 13.9m / totalStockholderEquity, last quarter 280.5m)
Debt / EBITDA = 1.69 (negative EBITDA) (Net Debt -293.7m / EBITDA -173.7m)
Debt / FCF = 1.75 (negative FCF - burning cash) (Net Debt -293.7m / FCF TTM -167.6m)
Total Stockholder Equity = 334.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.86% (Net Income -244.1m / Total Assets 326.8m)
RoE = -73.00% (Net Income TTM -244.1m / Total Stockholder Equity 334.4m)
RoCE = -51.16% (EBIT -175.3m / Capital Employed (Equity 334.4m + L.T.Debt 8.37m))
RoIC = -41.43% (negative operating profit) (NOPAT -138.5m / Invested Capital 334.4m)
WACC = 12.37% (E(474.8m)/V(488.7m) * Re(11.64%) + D(13.9m)/V(488.7m) * Rd(47.25%) * (1-Tc(0.21)))
Discount Rate = 11.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.15%
[DCF] Fair Price = unknown (Cash Flow -167.6m)
EPS Correlation: -8.79 | EPS CAGR: 7.42% | SUE: 0.16 | # QB: 0
Revenue Correlation: -22.16 | Revenue CAGR: -65.64% | SUE: -0.01 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.32 | Chg7d=+0.000 | Chg30d=+0.050 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-12-31): EPS=0.64 | Chg7d=-0.063 | Chg30d=+0.113 | Revisions Net=+2 | Growth EPS=+116.1% | Growth Revenue=+850.0%
EPS next Year (2027-12-31): EPS=-1.04 | Chg7d=-0.040 | Chg30d=+0.055 | Revisions Net=+1 | Growth EPS=-262.5% | Growth Revenue=-72.8%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)